What type of study is this?

This is a Case Report study (also classified as: Literature Review).

October 10, 2025Open Access

Profound Opioid and Medetomidine Withdrawal: A Case Series and Narrative Review of Available Literature

Key Points

Extreme withdrawal symptoms were observed in all four reported cases, highlighting a significant clinical concern.
The literature review underscores a lack of comprehensive studies on the withdrawal syndrome related to medetomidine and opioids.
Identification of atypical withdrawal phenotypes is critical, as awareness may improve early interventions in clinical settings.
Potential treatment avenues are limited, emphasizing the need for further research and clinical guidelines on medetomidine withdrawal.

Abstract

Medetomidine, a potent veterinary α2 agonist, has emerged as a fentanyl adulterant in the non-medical opioid supply. Its use has been linked to a novel withdrawal syndrome that is often resistant to conventional treatment protocols. Four cases are presented demonstrating extreme forms of this withdrawal syndrome. A literature review is provided showing both the paucity of available literature as well as potential avenues for treatment and future research. As adulterants continue to proliferate in the illicit drug supply, clinicians should anticipate atypical withdrawal phenotypes and consider early intervention.

Read Full Paperexternally

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

References and Citations

Add This Paper to Your Research Feed

Any time a new paper drops it will be there.